Please check your internet connection and try again.
# Sompraz HP (Pantoprazole)
## Overview
Sompraz HP is a combination product containing pantoprazole, a proton pump inhibitor (PPI), and specific antibiotics used for the eradication of *Helicobacter pylori* infection. Pantoprazole reduces gastric acid production, creating an environment that is more conducive to the efficacy of antibiotics.
## Primary Indications
Eradication of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
The typical adult dosing regimen for Sompraz HP involves a 7-day course. Specific components and dosages are:
* Pantoprazole 40 mg orally twice daily (before breakfast and before evening meal)
* Amoxicillin 1000 mg orally twice daily (before breakfast and before evening meal)
* Clarithromycin 500 mg orally twice daily (before breakfast and before evening meal)
## Pediatric Dosing
Sompraz HP is not typically recommended for pediatric use. Specific pediatric dosing for *H. pylori* eradication varies and should be guided by specialized guidelines or consultation.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is generally required for pantoprazole in mild to moderate renal impairment. Use with caution in severe renal impairment.
* **Hepatic Impairment:** In severe hepatic impairment, the maximum daily dose of pantoprazole should not exceed 20 mg.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of severe hypersensitivity reactions to penicillins or cephalosporins.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Use in patients with congenital long QT syndrome, known QT prolongation, clinically significant bradycardia, severe heart failure, or electrolyte disturbances (hypokalemia, hypomagnesemia) for clarithromycin.
## Adverse Effects
Common adverse effects may include:
* **Gastrointestinal:** Diarrhea, nausea, abdominal pain, constipation, vomiting.
* **Headache**
* **Dysgeusia** (altered taste)
* **Rash**
* **Allergic reactions** (including anaphylaxis)
* **QT interval prolongation** (associated with clarithromycin)
* **Clostridioides difficile-associated diarrhea**
## Key Drug Interactions
* **CYP2C19 and CYP3A4 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. It can increase the plasma concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, methotrexate). Clarithromycin is a strong inhibitor of CYP3A4. Co-administration with CYP3A4 substrates (e.g., certain statins, anticoagulants, calcium channel blockers) can lead to increased drug levels and potential toxicity.
* **Ketoconazole/Itraconazole:** Pantoprazole may decrease absorption of these antifungals.
* **Digoxin:** Pantoprazole may increase digoxin levels.
* **Antiretrovirals:** Clarithromycin can interact with various antiretrovirals, affecting their efficacy or toxicity.
* **Warfarin:** Clarithromycin may increase INR; monitor closely.
## Monitoring
* **Treatment Efficacy:** Confirmation of *H. pylori* eradication typically occurs 4-6 weeks after completing therapy, using stool antigen tests, urea breath tests, or biopsy-based methods.
* **Adverse Effects:** Monitor for signs and symptoms of hypersensitivity reactions, *C. difficile*-associated diarrhea, liver dysfunction, and QT interval prolongation.
* **Electrolytes:** Consider monitoring magnesium levels with prolonged pantoprazole use.
## Clinical Pearls
* Ensure the full 7-day course is completed as prescribed.
* Administer pantoprazole 30-60 minutes before meals.
* Patient education on potential side effects and the importance of reporting new or worsening symptoms is crucial.
* Consider antibiotic resistance patterns in the local area when assessing treatment failure.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines before making treatment decisions.*
